col blocks we are bridge builder col blocks
COVID Antworten in den wissenschaftlichen Zeitschriften der Welt


22 Ergebisse       Seite 1

 [1] 
Elsevier: Bioorganic & Medicinal Chemistry
  Original Artikel Datum Titel Autoren   Alle Autoren
1 [GO] 2024―Sep―12 Design of inhibitors of SARS-CoV-2 papain-like protease deriving from GRL0617: Structure-activity relationships Lukas Kerti, Vladimir Frecer
2 [GO] 2024―Jul―22 Discovery of macrocyclic covalent inhibitors for severe acute respiratory syndrome coronavirus 2 3CL protease Xiubo Tang, Kai Hou, Xiaowu Chen, Wenyuan Fan, Hao Wu, Changliang Wu, Gong-Xin He
3 [GO] 2024―Apr―18 Molecular basis of N-glycan recognition by pradimicin a and its potential as a SARS-CoV-2 entry inhibitor Yu Nakagawa, Masato Fujii, Nanaka Ito, Makoto Ojika, Dai Akase, Misako Aida, et al. (+5)
4 [GO] 2024―Jan―05 Exploiting high-energy hydration sites for the discovery of potent peptide aldehyde inhibitors of the SARS-CoV-2 main protease with cellular antiviral activity Daniel W. Carney, Abba E. Leffler, Jeffrey A. Bell, Asela S. Chandrasinghe, Cecilia Cheng, Edcon Chang, et al. (+14)
5 [GO] 2023―Nov―11 Identification of Ebselen Derivatives as Novel SARS-CoV-2 Main Protease Inhibitors: Design, Synthesis, Biological Evaluation, and Structure-Activity Relationships Exploration Heng Zhang, Jing Li, Karoly Toth, Ann E. Tollefson, Lanlan Jing, Shenghua Gao, et al. (+2)
6 [GO] 2023―Okt―12 Mass spectrometric assays monitoring the deubiquitinase activity of the SARS-CoV-2 papain-like protease inform on the basis of substrate selectivity and have utility for substrate identification Lennart Brewitz, H.T. Henry Chan, Petra Lukacik, Claire Strain-Damerell, Martin A. Walsh, Fernanda Duarte, Christopher J. Schofield
7 [GO] 2023―Jan―21 Design, synthesis, docking, and biochemical characterization of non-nucleoside SARS-CoV-2 RdRp inhibitors Nicoletta Brindani, Federico Munafò, Andrea Menichetti, Elisa Donati, Michela Nigro, Giuliana Ottonello, et al. (+2)
8 [GO] 2022―Mai―21 Discovery of honokiol thioethers containing 1,3,4-oxadiazole moieties as potential α-glucosidase and SARS-CoV-2 entry inhibitors Ting Xu, Jie-Ru Meng, Wanqing Cheng, Jia-Zheng Liu, Junyan Chu, Qian Zhang, et al. (+3)
9 [GO] 2022―Mai―11 Design, synthesis and evaluation of inhibitors of the SARS-CoV-2 nsp3 macrodomain Lavinia M. Sherrill, Elva E. Joya, AnnMarie Walker, Anuradha Roy, Yousef M. Alhammad, Moriama Atobatele, et al. (+9)
10 [GO] 2021―Nov―22 Synthesis and Evaluation of Enantiomers of Hydroxychloroquine Against SARS-CoV-2 in vitro Yong Ni, Jinbiao Liao, Zhenlong Qian, Chunxiu Wu, Xiangyu Zhang, Ji Zhang, et al. (+2)
11 [GO] 2021―Sep―20 A short survey of Dengue protease inhibitor development in the past 6 years (2015-2020) with an emphasis on similarities between DENV and SARS-CoV-2 proteases Sheikh Murtuja, Deepak Shilkar, Biswatrish Sarkar, Barij Nayan Sinha, Venkatesan Jayaprakash
12 [GO] 2021―Sep―14 Enzyme Inhibition as a Potential Therapeutic Strategy to Treat COVID-19 Infection Lukas Paulsson-Habegger, Andrew K. Snabaitis, Stephen P. Wren
13 [GO] 2021―Sep―04 Antiviral Evaluation of Hydroxyethylamine Analogs: Inhibitors of SARS-CoV-2 Main Protease (3CLpro), A Virtual Screening and Simulation Approach Yash Gupta, Sumit Kumar, Samantha E. Zak, Krysten A. Jones, Charu Upadhyay, Neha Sharma, et al. (+8)
14 [GO] 2021―Aug―13 Antiviral fungal metabolites and some insights into their contribution to the current COVID-19 pandemic Jacqueline Aparecida Takahashi, Bianca Vianna Rodrigues Barbosa, Matheus Thomaz Nogueira Silva Lima, Patrícia Gomes Cardoso, Christiane Contigli, Lúcia Pinheiro Santos Pimenta
15 [GO] 2021―Aug―11 Potency and Pharmacokinetics of GS-441524 Derivatives against SARS-CoV-2 Daibao Wei, Tianwen Hu, Yumin Zhang, Wei Zheng, Haitao Xue, Jingshan Shen, et al. (+2)
16 [GO] 2021―Jul―23 Potent antiviral activity of Agrimonia pilosa, Galla rhois, and their components against SARS-CoV-2 Yeong-Geun Lee, Kyung Won Kang, Woojae Hong, Yeon Hwa Kim, Jen Taek Oh, Dae Won Park, et al. (+6)
17 [GO] 2021―Jul―03 Synthetic and computational efforts towards the development of peptidomimetics and small-molecule SARS-CoV 3CLpro inhibitors: a review Abhik Paul, Arnab Sarkar, Sanjukta Saha, Avik Maji, Pritha Janah, Tapan Kumar Maity
18 [GO] 2021―Mrz―26 Identification of SARS-CoV-2 viral entry inhibitors using machine learning and cell-based pseudotyped particle assay Hongmao Sun, Yuhong Wang, Catherine Z. Chen, Miao Xu, Hui Guo, Misha Itkin, et al. (+2)
19 [GO] 2021―Jan―23 Potential inhibitors interacting in Neuropilin-1 to develop an adjuvant drug against COVID-19, by molecular docking José Luis Vique-Sánchez
20 [GO] 2020―Nov―06 Protease targeted COVID-19 drug discovery and its challenges: Insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors Sk. Abdul Amin, Suvankar Banerjee, Kalyan Ghosh, Shovanlal Gayen, Tarun Jha
21 [GO] 2020―Sep―10 COVID-19 therapy: what weapons do we bring into battle? Sinara Mônica Vitalino de Almeida, José Cleberson Santos Soares, Keriolaine Lima dos Santos, Josival Emanuel Ferreira Alves, Amélia Galdino Ribeiro, Íris Trindade Tenório Jacob, et al. (+5)
22 [GO] 2020―Sep―08 Druggable targets from coronaviruses for designing new antiviral drugs Leandro Rocha Silva, Paulo Fernando da Silva Santos-Júnior, Júlia de Andrade Brandão, Letícia Anderson, Ênio José Bassi, João Xavier de Araújo-Júnior, et al. (+2)
 [1] 

22 Ergebisse       Seite 1


[de][en]

Letzte Änderung 2023―Okt―27 12:08:13 UTC

© Daten-Quadrat 2022       Done in 0.003 sec